Hervolution has been awarded an EU grant to further explore the role of IPT001 in oncological immunotherapy approaches against hard to treat cancers

This initiative aims to advance our understanding of the potential applications of IPT001 in enhancing oncological immunotherapy, ultimately contributing to the development of more effective treatment strategies for cancer patients. “Significant progress has been made as Hervolution secures a substantial EU fund to expand its research efforts into utilizing IPT001 within the field of oncological […]